Rationale and Design of the Double-Blind, Randomized, Placebo-Controlled Multicenter Trial on Efficacy of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER)

Chang PP(2014)Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the atherosclerosis risk in communities study) Am J Cardiol 113 504-10

Chambless LE(2013)ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Cir J: Off J Jpn Circ Soc 77 2157-201

Shahar E(2012)The past, present and future of renin-angiotensin aldosterone system inhibition Eur J Heart Fail 14 803-69

McMurray JJ(2013)Influence of global region on outcomes in heart failure beta-blocker trials Int J Cardiol 167 1677-87

Adamopoulos S(2011)Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry J Am Coll Cardiol 58 915-22

Anker SD(2004)Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND registry) Heart Fail Rev 9 179-85

Mentz RJ(2013)The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators Circ J: Off J Jpn Circ Soc 77 944-51

Bakris GL(1999)Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 341 709-17

Waeber B(2003)Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial N Engl J Med 348 1309-21

O’Connor CM(2013)A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial Eur J Heart Fail 15 1228-35

Chang PP(2014)Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the atherosclerosis risk in communities study) Am J Cardiol 113 504-10

Chambless LE(2013)ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European society of cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Cir J: Off J Jpn Circ Soc 77 2157-201

Shahar E(2012)The past, present and future of renin-angiotensin aldosterone system inhibition Eur J Heart Fail 14 803-69

McMurray JJ(2013)Influence of global region on outcomes in heart failure beta-blocker trials Int J Cardiol 167 1677-87

Adamopoulos S(2011)Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry J Am Coll Cardiol 58 915-22

Anker SD(2004)Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND registry) Heart Fail Rev 9 179-85

Mentz RJ(2013)The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators Circ J: Off J Jpn Circ Soc 77 944-51

Bakris GL(1999)Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 341 709-17

Waeber B(2003)Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial N Engl J Med 348 1309-21

O’Connor CM(2013)A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial Eur J Heart Fail 15 1228-35